@article{JGO25308,
author = {Kelvin Allenson and David Roife and Lillian S. Kao and Tien C. Ko and Curtis J. Wray},
title = {Estimation of hepatocellular carcinoma mortality using aspartate aminotransferase to platelet ratio index},
journal = {Journal of Gastrointestinal Oncology},
volume = {11},
number = {2},
year = {2018},
keywords = {},
abstract = {Background: Hepatocellular carcinoma (HCC) patients with cirrhosis are high-risk for invasive procedures. Identification of those at risk may prevent complications and allow more informed decision-making. The aspartate aminotransferase (AST) to platelet ratio index (APRI) is a measure of cirrhosis that we hypothesize predicts survival and may estimate HCC mortality.
Methods: Institutional retrospective study of all HCC patients. Demographics and labs [bilirubin, international normalized ratio (INR), creatinine, AST and platelets] were recorded at the date-of-diagnosis to calculate APRI and the Model for End-Stage Liver Disease score (MELD). Poor survival was defined as death within 30-days from diagnosis. Models were created to determine predictors of death within 30-days and overall survival.
Results: A total of 829 patients comprised this study and },
issn = {2219-679X}, url = {https://jgo.amegroups.org/article/view/25308}
}